Impact of plasma Lp-PLA2 activity on the progression of aortic stenosis: The PROGRESSA study

JACC: Cardiovascular Imaging

Volumn 8, Issue 1, 2015, Pages 26-33

  Capoulade, Romain ^a   Mahmut, Ablajan ^a   Tastet, Lionel ^a   Arsenault, Marie ^a   Bédard, Élisabeth ^a   Dumesnil, Jean G ^a   Després, Jean Pierre ^a   Larose, Éric ^a   Arsenault, Benoit J ^a   Bossé, Yohan ^a   Mathieu, Patrick ^a   Pibarot, Philippe ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Aortic stenosis; Calcific aortic valve disease; Doppler echocardiography; Lipoprotein associated phospholipase A2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ANTIHYPERTENSIVE THERAPY; AORTA VALVE STENOSIS; AORTIC VALVE AREA INDEX; ARTICLE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MINERALIZATION; PATIENT ASSESSMENT; PEAK AORTIC JET VELOCITY; PRESSURE GRADIENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SEX DIFFERENCE; SYSTEMIC DISEASE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VELOCITY; AORTA VALVE; BLOOD; HEART LEFT VENTRICLE FUNCTION; PATHOLOGY; PATHOPHYSIOLOGY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AORTIC VALVE; AORTIC VALVE STENOSIS; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 84942758268     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2014.09.016     Document Type: Article

References (46)

1. Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation 2011;124:1783-91.
2. Mohty D, Pibarot P, Despres JP, et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008;28:187-93.
3. Côté N, Pibarot P, Pepin A, et al. Oxidized low-density lipoprotein, angiotensin II and increased waist circumference are associated with valve inflammation in prehypertensive patients with aortic stenosis. Int J Cardiol 2009; 145:444-9.
4. Côté C, Pibarot P, Despres JP, et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008;94:1175-80.
5. Macphee CH, Nelson JJ, Zalewski A. Lipoprotein- associated phospholipase A2 as a target of therapy. Curr Opin Lipidol 2005;16:442-6.
6. Mahmut A, Boulanger MC, El Husseini D, et al. Elevated expression of Lp-PLA2 in calcific aortic valve disease: implication for valve mineralization. J Am Coll Cardiol 2014;63:460-9.
7. Kolasa-Trela R, Fil K, Bazanek M, et al. Lipoprotein- associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis. Clin Chem Lab Med 2012;50:1825-31.
8. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611-7.
9. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenosis. J Am Coll Cardiol 2009;54:1003-11.
10. Suchindran S, Rivedal D, Guyton JR, et al. Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. PLoS Genet 2010;6:e1000928.
11. Macphee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999;338(Pt 2):479-87.
12. Aiyar N, Disa J, Ao Z, et al. Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells. Mol Cell Biochem 2007;295:113-20.
13. Macphee CH, Nelson J, Zalewski A. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol 2006;6:154-61.
14. Newby DE, Cowell SJ, Boon NA. Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both? Heart 2006;92:729-34.
15. Antonini-Canterin F, Hirsu M, Popescu BA, et al. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 2008;102:738-42.
16. Rajamannan NM. Mechanisms of aortic valve calcification: the LDL-density-radius theory: a translation from cell signaling to physiology. Am J Physiol Heart Circ Physiol 2010;298:H5-15.
17. Messika-Zeitoun D, Bielak LF, Peyser PA, et al. Aortic valve calcification: determinants and progression in the population. Arterioscler Thromb Vasc Biol 2007;27:642-8.
18. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996;16:523-32.
19. O'Brien KD, Shavelle DM, Caulfield MT, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002; 106:2224-30.
20. Otto CM, Prendergast B. Aortic-valve stenosis- from patients at risk to severe valve obstruction. N Engl J Med 2014;371:744-56.
21. Hekimian G, Boutten A, Flamant M, et al. Progression of aortic valve stenosis is associated with bone remodelling and secondary hyperparathyroidism in elderly patients-the COFRASA study. Eur Heart J 2013;34:1915-22.
22. Dweck MR, Jenkins WS, Vesey AT, et al. 18F-NaF uptake Is a marker of active calcification and disease progression in patients with aortic stenosis. Circ Cardiovasc Imaging 2014;7:371-8.
23. Briand M, Lemieux I, Dumesnil JG, et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006;47:2229-36.
24. Capoulade R, Clavel MA, Dumesnil JG, et al. Impact of metabolic syndrome on progression of aortic stenosis: Influence of age and statin therapy. J Am Coll Cardiol 2012;60:216-23.
25. Katz R, Wong ND, Kronmal R, et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi- Ethnic Study of Atherosclerosis. Circulation 2006; 113:2113-9.
26. Katz R, Budoff MJ, Takasu J, et al. Relationship of metabolic syndrome to incident aortic valve calcium and aortic valve calcium progression: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes 2009;58:813-9.
27. Mohty D, Pibarot P, Despres JP, et al. Agerelated differences in the pathogenesis of calcific aortic stenosis: the potential role of resistin. Int J Cardiol 2010;142:126-32.
28. Mohty D, Pibarot P, Côté N, et al. Hypoadiponectinemia is associated with valvular inflammation and faster disease progression in patients with aortic stenosis. Cardiology 2011;118:140-6.
29. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992;93: 189-99.
30. St Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001;104:2295-9.
31. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999;25: 199-211.
32. Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012;60:716-21.
33. Spence JD, Koschinsky M. Mechanisms of lipoprotein( a) pathogenicity: prothrombotic, proatherosclerotic, or both? Arterioscler Thromb Vasc Biol 2012;32:1550-1.
34. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014;63:470-7.
35. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368:503-12.
36. Hung MY, Witztum JL, Tsimikas S. New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis. J Am Coll Cardiol 2014;63:478-80.
37. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97.
38. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343-56.
39. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis. Results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121:306-14.
40. Gerdts E, Rossebo AB, Pedersen TR, et al. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study). Am J Cardiol 2010;106:1634-9.
41. Derbali H, Bossé Y, Côté N, et al. Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via toll-like receptor 2. Am J Pathol 2010;176: 2638-45.
42. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Despres JP. Visceral obesity and the heart. Int J Biochem Cell Biol 2008;40:821-36.
43. Mathieu P, Lemieux I, Despres JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther 2010;87:407-16.
44. Tsimikas S, Willeit J, Knoflach M, et al. Lipoprotein- associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J 2009; 30:107-15.
45. STABILITY Investigators, White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370:1702-11.
46. O'Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014;312:1006-15.